Edition:
United Kingdom

Genkyotex says WHO recommended setanaxib as international nonproprietary name for GKT831


Monday, 22 Jul 2019 

July 22 (Reuters) - GENKYOTEX SA ::REG-THE WHO RECOGNIZES NOX INHIBITORS AS NEW THERAPEUTIC CLASS AND APPROVES SETANAXIB FOR GKT831.WORLD HEALTH ORGANIZATION (WHO) RECOGNIZED GKT831 AS FIRST REPRESENTATIVE OF NOX INHIBITOR THERAPEUTIC CLASS.RECOMMENDED NEW STEM "NAXIB" RECOGNIZES NOX INHIBITORS AS A NEW THERAPEUTIC CLASS.NOX INHIBITOR THERAPEUTIC CLASS HAS SIGNIFICANT POTENTIAL IN FIBROTIC, INFLAMMATORY, NEURODEGENERATIVE, AND ONCOLOGY DISORDERS.A SECOND PHASE 2 STUDY IS ONGOING IN DIABETIC PATIENTS WITH KIDNEY FIBROSIS.US FOOD AND DRUG ADMINISTRATION (FDA) RECENTLY APPROVED INITIATION OF AN ADDITIONAL PHASE 2 TRIAL IN PATIENTS WITH PATIENTS WITH IPF.. 

Company Quote

3.85
0.025 +0.65%
23 Aug 2019